Modus Therapeutics Receives Approval for Phase 2 Study
Karolinska Development's portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of a phase 2 study with sevuparin as a treatment for chronic kidney disease with anemia.
The study, set to start in Q4 2025, will evaluate three doses of sevuparin in patients with chronic kidney disease with anemia, based on single-dose data from the initial part of the study, which showed that sevuparin was well-tolerated.
Modus Therapeutics has received approval from regulatory authorities in Italy to initiate the second part of the company's phase 2 study with sevuparin.
The approval is in line with the company's development timeline, and the study will be conducted by Modus Therapeutics, listed on Nasdaq First North Growth Market.
Author's summary: Modus Therapeutics gets approval for phase 2 study.